Peripheral Dopamine Receptors

Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam > dopamine > dipropyl dopamine > apomorphine cha...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hypertension 1990-06, Vol.3 (6-Pt-2), p.25S-28S
1. Verfasser: Kohli, J D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 28S
container_issue 6-Pt-2
container_start_page 25S
container_title American journal of hypertension
container_volume 3
creator Kohli, J D
description Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam > dopamine > dipropyl dopamine > apomorphine characterizes the DA1 receptor while the reverse order: apomorphine > dipropyl dopamine ≥ dopamine >>> fenoldopam distinguishes the DA2 subtype. SCH 23390 for the DA1 and domperidone and (S)-sulpiride for the DA2, as selective antagonists, clearly identify the two subtypes. Increase in cyclic AMP after DA1 activation and decrease after DA2 occupancy have been reported. However, how both increase and decrease in cyclic AMP transduce vascular relaxation remains to be explained. DA1 and DA2 agonist activities of two new structures, CY 208,243 (Sandoz) and dihydrexidine, are reported in this chapter. Addition of benzene to ergoline and benzoquinoline moieties rendered these molecules inactive on the DA2 receptor while bestowing DA1 agonist activity on these otherwise inactive molecules and even obviated the need for two OH groups for DA1 activity. It would appear that the current views on structural requirements for DA1 and DA2 agonist activities will require revision and reexamination. Am J Hypertens 1990;3:25S-28S
doi_str_mv 10.1093/ajh/3.6.25S
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79932719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79932719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c364t-a3e47a5d5aa20e7ceaa5949b92d9036b02c0afc433dedc502fcc9fcbe65d7c263</originalsourceid><addsrcrecordid>eNo9kEtLw0AUhQdRaq2uXBe6ciNp5z2dpdZHhVJFK4ib4WZyQ1PTJs6koP_eSEtXd_F9nMM9hFwyOmTUihGsliMx1EOu3o5Il1nJEsO5OiZdOrYqMVSzU3IW44pSKrVmHdLhTAoxVl3Sf8FQ1EsMUA7uqhrWxQYHr-ixbqoQz8lJDmXEi_3tkfeH-8VkmsyeH58mN7PECy2bBARKAypTAJyi8QigrLSp5ZmlQqeUewq5byszzLyiPPfe5j5FrTLjuRY9crXLrUP1vcXYuHURPZYlbLDaRmesFdww24rXO9GHKsaAuatDsYbw6xh1_2O4dgwnnHbtGK3d38du0zVmB3f_fcuTHS9igz8HDOHLaSOMctOPT6cXc3k7l8Ldij8T1Wkt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79932719</pqid></control><display><type>article</type><title>Peripheral Dopamine Receptors</title><source>MEDLINE</source><source>Oxford University Press Journals Digital Archive Legacy</source><creator>Kohli, J D</creator><creatorcontrib>Kohli, J D</creatorcontrib><description>Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam &gt; dopamine &gt; dipropyl dopamine &gt; apomorphine characterizes the DA1 receptor while the reverse order: apomorphine &gt; dipropyl dopamine ≥ dopamine &gt;&gt;&gt; fenoldopam distinguishes the DA2 subtype. SCH 23390 for the DA1 and domperidone and (S)-sulpiride for the DA2, as selective antagonists, clearly identify the two subtypes. Increase in cyclic AMP after DA1 activation and decrease after DA2 occupancy have been reported. However, how both increase and decrease in cyclic AMP transduce vascular relaxation remains to be explained. DA1 and DA2 agonist activities of two new structures, CY 208,243 (Sandoz) and dihydrexidine, are reported in this chapter. Addition of benzene to ergoline and benzoquinoline moieties rendered these molecules inactive on the DA2 receptor while bestowing DA1 agonist activity on these otherwise inactive molecules and even obviated the need for two OH groups for DA1 activity. It would appear that the current views on structural requirements for DA1 and DA2 agonist activities will require revision and reexamination. Am J Hypertens 1990;3:25S-28S</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1093/ajh/3.6.25S</identifier><identifier>PMID: 2143385</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Animals ; Blood Pressure - drug effects ; Blood Vessels - metabolism ; Chemical Phenomena ; Chemistry ; CY 208 ; DA1/DA2 subtypes ; dihydrexidine ; Dopamine - pharmacology ; Humans ; Indoles - pharmacology ; Peripheral dopamine receptors ; Phenanthridines - pharmacology ; Receptors, Dopamine - metabolism ; Receptors, Dopamine - physiology ; Receptors, Dopamine D1 ; Receptors, Dopamine D2 ; structure activity relationships ; Structure-Activity Relationship ; Vasodilation - physiology</subject><ispartof>American journal of hypertension, 1990-06, Vol.3 (6-Pt-2), p.25S-28S</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c364t-a3e47a5d5aa20e7ceaa5949b92d9036b02c0afc433dedc502fcc9fcbe65d7c263</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2143385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kohli, J D</creatorcontrib><title>Peripheral Dopamine Receptors</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description>Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam &gt; dopamine &gt; dipropyl dopamine &gt; apomorphine characterizes the DA1 receptor while the reverse order: apomorphine &gt; dipropyl dopamine ≥ dopamine &gt;&gt;&gt; fenoldopam distinguishes the DA2 subtype. SCH 23390 for the DA1 and domperidone and (S)-sulpiride for the DA2, as selective antagonists, clearly identify the two subtypes. Increase in cyclic AMP after DA1 activation and decrease after DA2 occupancy have been reported. However, how both increase and decrease in cyclic AMP transduce vascular relaxation remains to be explained. DA1 and DA2 agonist activities of two new structures, CY 208,243 (Sandoz) and dihydrexidine, are reported in this chapter. Addition of benzene to ergoline and benzoquinoline moieties rendered these molecules inactive on the DA2 receptor while bestowing DA1 agonist activity on these otherwise inactive molecules and even obviated the need for two OH groups for DA1 activity. It would appear that the current views on structural requirements for DA1 and DA2 agonist activities will require revision and reexamination. Am J Hypertens 1990;3:25S-28S</description><subject>Animals</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Vessels - metabolism</subject><subject>Chemical Phenomena</subject><subject>Chemistry</subject><subject>CY 208</subject><subject>DA1/DA2 subtypes</subject><subject>dihydrexidine</subject><subject>Dopamine - pharmacology</subject><subject>Humans</subject><subject>Indoles - pharmacology</subject><subject>Peripheral dopamine receptors</subject><subject>Phenanthridines - pharmacology</subject><subject>Receptors, Dopamine - metabolism</subject><subject>Receptors, Dopamine - physiology</subject><subject>Receptors, Dopamine D1</subject><subject>Receptors, Dopamine D2</subject><subject>structure activity relationships</subject><subject>Structure-Activity Relationship</subject><subject>Vasodilation - physiology</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLw0AUhQdRaq2uXBe6ciNp5z2dpdZHhVJFK4ib4WZyQ1PTJs6koP_eSEtXd_F9nMM9hFwyOmTUihGsliMx1EOu3o5Il1nJEsO5OiZdOrYqMVSzU3IW44pSKrVmHdLhTAoxVl3Sf8FQ1EsMUA7uqhrWxQYHr-ixbqoQz8lJDmXEi_3tkfeH-8VkmsyeH58mN7PECy2bBARKAypTAJyi8QigrLSp5ZmlQqeUewq5byszzLyiPPfe5j5FrTLjuRY9crXLrUP1vcXYuHURPZYlbLDaRmesFdww24rXO9GHKsaAuatDsYbw6xh1_2O4dgwnnHbtGK3d38du0zVmB3f_fcuTHS9igz8HDOHLaSOMctOPT6cXc3k7l8Ldij8T1Wkt</recordid><startdate>19900601</startdate><enddate>19900601</enddate><creator>Kohli, J D</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900601</creationdate><title>Peripheral Dopamine Receptors</title><author>Kohli, J D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c364t-a3e47a5d5aa20e7ceaa5949b92d9036b02c0afc433dedc502fcc9fcbe65d7c263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Animals</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Vessels - metabolism</topic><topic>Chemical Phenomena</topic><topic>Chemistry</topic><topic>CY 208</topic><topic>DA1/DA2 subtypes</topic><topic>dihydrexidine</topic><topic>Dopamine - pharmacology</topic><topic>Humans</topic><topic>Indoles - pharmacology</topic><topic>Peripheral dopamine receptors</topic><topic>Phenanthridines - pharmacology</topic><topic>Receptors, Dopamine - metabolism</topic><topic>Receptors, Dopamine - physiology</topic><topic>Receptors, Dopamine D1</topic><topic>Receptors, Dopamine D2</topic><topic>structure activity relationships</topic><topic>Structure-Activity Relationship</topic><topic>Vasodilation - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kohli, J D</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kohli, J D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peripheral Dopamine Receptors</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>1990-06-01</date><risdate>1990</risdate><volume>3</volume><issue>6-Pt-2</issue><spage>25S</spage><epage>28S</epage><pages>25S-28S</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><abstract>Since 1979 when two subtypes of peripheral dopamine receptors (DA1 and DA2) were first proposed, much progress has been made to confirm such a view. Cumulative experience with the dog in vivo models suggests that the potency order: fenoldopam &gt; dopamine &gt; dipropyl dopamine &gt; apomorphine characterizes the DA1 receptor while the reverse order: apomorphine &gt; dipropyl dopamine ≥ dopamine &gt;&gt;&gt; fenoldopam distinguishes the DA2 subtype. SCH 23390 for the DA1 and domperidone and (S)-sulpiride for the DA2, as selective antagonists, clearly identify the two subtypes. Increase in cyclic AMP after DA1 activation and decrease after DA2 occupancy have been reported. However, how both increase and decrease in cyclic AMP transduce vascular relaxation remains to be explained. DA1 and DA2 agonist activities of two new structures, CY 208,243 (Sandoz) and dihydrexidine, are reported in this chapter. Addition of benzene to ergoline and benzoquinoline moieties rendered these molecules inactive on the DA2 receptor while bestowing DA1 agonist activity on these otherwise inactive molecules and even obviated the need for two OH groups for DA1 activity. It would appear that the current views on structural requirements for DA1 and DA2 agonist activities will require revision and reexamination. Am J Hypertens 1990;3:25S-28S</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>2143385</pmid><doi>10.1093/ajh/3.6.25S</doi></addata></record>
fulltext fulltext
identifier ISSN: 0895-7061
ispartof American journal of hypertension, 1990-06, Vol.3 (6-Pt-2), p.25S-28S
issn 0895-7061
1941-7225
language eng
recordid cdi_proquest_miscellaneous_79932719
source MEDLINE; Oxford University Press Journals Digital Archive Legacy
subjects Animals
Blood Pressure - drug effects
Blood Vessels - metabolism
Chemical Phenomena
Chemistry
CY 208
DA1/DA2 subtypes
dihydrexidine
Dopamine - pharmacology
Humans
Indoles - pharmacology
Peripheral dopamine receptors
Phenanthridines - pharmacology
Receptors, Dopamine - metabolism
Receptors, Dopamine - physiology
Receptors, Dopamine D1
Receptors, Dopamine D2
structure activity relationships
Structure-Activity Relationship
Vasodilation - physiology
title Peripheral Dopamine Receptors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A33%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peripheral%20Dopamine%20Receptors&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Kohli,%20J%20D&rft.date=1990-06-01&rft.volume=3&rft.issue=6-Pt-2&rft.spage=25S&rft.epage=28S&rft.pages=25S-28S&rft.issn=0895-7061&rft.eissn=1941-7225&rft_id=info:doi/10.1093/ajh/3.6.25S&rft_dat=%3Cproquest_cross%3E79932719%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79932719&rft_id=info:pmid/2143385&rfr_iscdi=true